IBU
LOE ApproachingNDAORALSUSPENSION
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IBU is an oral suspension small-molecule NDA approved in 1989 by Abbott. The specific indication and mechanism of action are not documented in available data. This product is in the mature/declining phase of its lifecycle with loss of exclusivity approaching.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a defensive/optimization-focused commercial team rather than growth mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
Started Nov 2026
59 enrolled
KeratosisActinic Keratoses
Phase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDAC
Started Aug 2026
20 enrolled
Glioblastoma Multiforme (GBM)Pancreatic Ductal Adenocarcinoma (PDAC)
Effects of Vagus Nerve Stimulation on Temporomandibular Disorders.
Started Aug 2026
10 enrolled
TMDTemporomandibular Disorders (TMDs)
Magnetic Ressonance Imaging of Temporomandibular Joint
Started Aug 2026
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
Started Jul 2026
84 enrolled
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
Worked on IBU at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.